ASP2998 for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Dec 2025: Trial registered, NCT07287995
  2. 5 Feb 2026: Trial started, NCT07287995

The trials

NCT07287995: A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
428 planned
Started
5 Feb 2026
Primary completion
30 Jun 2029
Arms
ASP2998 Dose Escalation, ASP2998 Dose Expansion, ASP2998 Monotherapy Dose Escalation (Tumor Specific), ASP2998 Monotherapy Dose Expansion (Tumor Specific)
Results
None posted
  1. 17 Dec 2025: Trial registered
  2. 5 Feb 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.